Scientists from the University of Chicago have modified a variant of Bifidobacterium longum, a probiotic bacterium naturally occurring in the digestive system and yogurt, to penetrate pancreatic tumors and function as a drug-producing entity targeting these growths. In experiments with animals, the modified strain, named BifidoSumIL-2, effectively delivered an immune-boosting protein directly into tumors, activating T cells that fight cancer and reducing the growth of pancreatic tumors. The most significant impact was observed when this method was used alongside chemotherapy, radiation, or immunotherapy. Historically, pancreatic cancer has been resistant to immunotherapy due to the tumors creating an inhospitable.
Disclosure:
This video contains stock footage and content created or enhanced using AI-assisted tools.
ai-generated
